Patents by Inventor Francisco Caballero
Francisco Caballero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230123802Abstract: Described herein are RPE cells engineered to secrete a FVII protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating a patient with hemophilia or FVII deficiency.Type: ApplicationFiled: March 27, 2020Publication date: April 20, 2023Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton, Zoe Yin
-
Publication number: 20220267794Abstract: Described herein are RPE cells engineered to secrete a GLA protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating Fabry disease.Type: ApplicationFiled: March 27, 2020Publication date: August 25, 2022Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Jeffrey Charles Way, Paul Kevin Wotton, Zoe Yin, Elina Makino, Brian Richard Fluharty, Marianthi Papakosta
-
Publication number: 20220000789Abstract: Described herein are implantable devices comprising means for mitigating the foreign body response (FBR) and at least one cell-containing compartment which comprises a plurality of cells (e.g., live cells) encapsulated in a polymer composition comprising a cell-binding substance (CBS), as well as compositions and methods of making and using the same. The cells are capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.Type: ApplicationFiled: September 27, 2019Publication date: January 6, 2022Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Owen O'Connor, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton, Zoe Yin
-
Publication number: 20210145759Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.Type: ApplicationFiled: March 27, 2019Publication date: May 20, 2021Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Matthias Alexander Oberli, Owen O'Connor, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton
-
Patent number: 10865213Abstract: The present disclosure provides compounds of Formula (I?), Formula (I), Formula (II), Formula (II-A), Formula (III), and Formula (IV). The compounds described herein are MAX binders and/or modulators of Myc, Mad, or Mxi1 (e.g., inhibitors of Myc, Mad, or Mxi1), and may be useful in treating a subject with a disease associated with Myc, such as proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions and kits including the compounds described herein, as well as methods of using and uses of the compounds, compositions, and kits.Type: GrantFiled: October 22, 2018Date of Patent: December 15, 2020Assignee: Massachusetts Institute of TechnologyInventors: Angela N. Koehler, Eric Stefan, Francisco Caballero, Dylan Vijith Neel, Nicholas B. Struntz, Helen L. Evans, Andrew Chen
-
Publication number: 20200263196Abstract: Described herein are cell compositions comprising an active cell (e.g., an engineered active cell, e.g., an engineered RPE cell) or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an active cell, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.Type: ApplicationFiled: September 27, 2018Publication date: August 20, 2020Inventors: Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Robert James Miller, Matthias Alexander Oberli, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton
-
Publication number: 20200048276Abstract: The present disclosure provides compounds of Formula (I-a), Formula (I), and Formula (II). The compounds described herein may be Myc modulators (e.g., Myc inhibitors) and may be useful in treating in a subject in need thereof diseases associated with Myc and proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.Type: ApplicationFiled: June 11, 2018Publication date: February 13, 2020Applicant: Massachusetts Institute of TechnologyInventors: Angela N. Koehler, Eric Stefan, Francisco Caballero
-
Publication number: 20190144466Abstract: The present disclosure provides compounds of Formula (I?), Formula (I), Formula (II), Formula (II-A), Formula (III), and Formula (IV). The compounds described herein are MAX binders and/or modulators of Myc, Mad, or Mxi1 (e.g., inhibitors of Myc, Mad, or Mxi1), and may be useful in treating a subject with a disease associated with Myc, such as proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions and kits including the compounds described herein, as well as methods of using and uses of the compounds, compositions, and kits.Type: ApplicationFiled: October 22, 2018Publication date: May 16, 2019Applicant: Massachusetts Institute of TechnologyInventors: Angela N. Koehler, Eric Stefan, Francisco Caballero, Dylan Vijith Neel, Nicholas B. Struntz, Helen L. Evans, Andrew Chen
-
Patent number: 10106555Abstract: The present disclosure provides compounds of Formula (I?), Formula (I), Formula (II), Formula (II-A), Formula (III), and Formula (IV). The compounds described herein are MAX binders and/or modulators of Myc, Mad, or Mxi1 (e.g., inhibitors of Myc, Mad, or Mxi1), and may be useful in treating a subject with a disease associated with Myc, such as proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions and kits including the compounds described herein, as well as methods of using and uses of the compounds, compositions, and kits.Type: GrantFiled: February 16, 2017Date of Patent: October 23, 2018Assignee: Massachusetts Institute of TechnologyInventors: Angela N. Koehler, Eric Stefan, Francisco Caballero, Dylan Vijith Neel, Nicholas B. Struntz, Helen L. Evans, Andrew Chen
-
Publication number: 20180291035Abstract: The present disclosure provides compounds of Formula (I-a), Formula (I), and Formula (II). The compounds described herein may be Myc modulators (e.g., Myc inhibitors) and may be useful in treating in a subject in need thereof diseases associated with Myc and proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.Type: ApplicationFiled: June 11, 2018Publication date: October 11, 2018Applicant: Massachusetts Institute of TechnologyInventors: Angela N. Koehler, Eric Stefan, Francisco Caballero
-
Patent number: 10017520Abstract: The present disclosure provides compounds of Formula (I-a), Formula (I), and Formula (II). The compounds described herein may be Myc modulators (e.g., Myc inhibitors) and may be useful in treating in a subject in need thereof diseases associated with Myc and proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.Type: GrantFiled: December 10, 2015Date of Patent: July 10, 2018Assignee: Massachusetts Institute of TechnologyInventors: Angela N. Koehler, Eric Stefan, Francisco Caballero
-
Publication number: 20170233405Abstract: The present disclosure provides compounds of Formula (I?), Formula (I), Formula (II), Formula (II-A), Formula (III), and Formula (IV). The compounds described herein are MAX binders and/or modulators of Myc, Mad, or Mxi1 (e.g., inhibitors of Myc, Mad, or Mxi1), and may be useful in treating a subject with a disease associated with Myc, such as proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions and kits including the compounds described herein, as well as methods of using and uses of the compounds, compositions, and kits.Type: ApplicationFiled: February 16, 2017Publication date: August 17, 2017Inventors: Angela N. Koehler, Eric Stefan, Francisco Caballero, Dylan Vijith Neel, Nicholas B. Struntz, Helen L. Evans, Andrew Chen
-
Publication number: 20160168165Abstract: The present disclosure provides compounds of Formula (I-a), Formula (I), and Formula (II). The compounds described herein may be Myc modulators (e.g., Myc inhibitors) and may be useful in treating in a subject in need thereof diseases associated with Myc and proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.Type: ApplicationFiled: December 10, 2015Publication date: June 16, 2016Inventors: Angela N. Koehler, Eric Stefan, Francisco Caballero